Evidence map›Paper›PMID 22100745›Full record

ReviewProstaglandins & other lipid mediators2012

Epoxyeicosatrienoic acids and heme oxygenase-1 interaction attenuates diabetes and metabolic syndrome complications.

Angela Burgess, Luca Vanella, Lars Bellner, Michal L Schwartzman, Nader G Abraham

Open access · greenAbstract readReview
In one paragraph

Review in Prostaglandins & other lipid mediators, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 41 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Review
  5. HO-1 overexpression and underexpression: Clinical implications.Archives of biochemistry and biophysics · 2019
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Eicosanoids in metabolic syndrome.Advances in pharmacology (San Diego, Calif.) · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Angela BurgessDepartment of Physiology and Pharmacology, University of Toledo College of Medicine, Toledo, OH 43614, USA.
Luca Vanella
Lars Bellner
Michal L Schwartzman
Nader G Abraham
University of Toledo · USNew York Medical College · US

Funding

Vasoregulatory Function of CYP2E1-Derived EicosanoidsP01HL034300 · NHLBI · NEW YORK MEDICAL COLLEGE · PI SCHWARTZMAN, MICHAL LANIADO · 1985 to 2015
$33.4M
HEME OXYGENASE REGULATION OF EICOSANOID BIOSYNTHESISR01DK056601 · NIDDK · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI ABRAHAM, NADER G. · 2001 to 2013
$4.4M
Oxidative Stress and Vascular HO in DiabetesR01DK068134 · NIDDK · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI ABRAHAM, NADER G. · 2006 to 2010
$1.7M
NHLBI NIH HHS P01 HL034300NIDDK NIH HHS R01 DK056601NIDDK NIH HHS R01 DK068134
6 · The paper itself

Abstract

MSCs are considered to be the natural precursors to adipocyte development through the process of adipogenesis. A link has been established between decreased protective effects of EETs or HO-1 and their interaction in metabolic syndrome. Decreases in HO-1 or EET were associated with an increase in adipocyte stem cell differentiation and increased levels of inflammatory cytokines. EET agonist (AKR-I-27-28) inhibited MSC-derived adipocytes and decreased the levels of inflammatory cytokines. We further describe the role of CYP-epoxygenase expression, HO expression, and circulating cytokine levels in an obese mouse, ob/ob(-/-) mouse model. Ex vivo measurements of EET expression within MSCs derived from ob/ob(-/-) showed decreased levels of EETs that were increased by HO induction. This review demonstrates that suppression of HO and EET systems exist in MSCs prior to the development of adipocyte dysfunction. Further, adipocyte dysfunction can be ameliorated by induction of HO-1 and CYP-epoxygenase, i.e. EET.

Indexed as

8,11,14-Eicosatrienoic AcidAnimalsDiabetes ComplicationsHeme Oxygenase-1HumansMetabolic SyndromeProtein Binding8,11,14-Eicosatrienoic AcidHeme Oxygenase-1

Identifiers

PMID22100745
PMCPMC3261364
OpenAlexW1984222509

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.